Clinical Trial Search

Primary: Participants With a Complete Response for Cytokine Release Syndrome (CRS) — 15 Participants

Primary: Percentage of Participants Who Developed ≥Grade 2 Cytokine Release Syndrome (CRS) by Day 14 After Immune Effector Cell (IEC) Therapy, Assessed by Using American Society…

Primary: Absence of Any Grade Cytokine Release Syndrome (CRS) — 16; 9 Participants

Primary: Subjects Discharged From the Hospital Alive and Without the Need for Mechanical Ventilation. — 10; 10 Participants

Primary: Rate of Neurotoxicity as Per CTCAE v4.03 Criteria — 3; 2; 5; 1 Participants

Primary: C-reactive Protein (CRP) Levels at Baseline and Day 14 — 75.45; 59.8; 41.9; 38.7 mg/L

Primary: IL-6 — 0; 0; 0; 0 pg/ml

Primary: Participants Who Survived Without Requiring Invasive Mechanical Ventilation From Day 3 to Day 29, Primary Analysis — 198; 191 Participants — p=0.2874

Primary: Time to Clinical Improvement — 12; 12; 11; 12 days

Primary: Change From Baseline to Week-6 (Part A) Endpoint in Mean Key Symptom Score (KSS) — 2.4; 3.1; 2.1; 0.5 Units of a Scale — p=<.0001

Primary: Number of Participants With Clinical Response in Maximum Temperature (Tmax) — 8; 16 Participants

Primary: Percentage of Participants With WHO Clinical Progression Scale > 5 at Day 4 -- Severe COVID Population (WHO Clinical Progression Scale =5 at Baseline) — 19; 28…

Primary: Number of Subjects Alive and Free of Respiratory Failure — 26; 20 Participants — p=0.0440

Primary: Incidence of Any Grade Cytokine Release Syndrome (CRS) — 10; 9 Participants

Primary: Number of Participants That Received YESCARTA — 20 Participants

Primary: Change in Inflammation Marker — -43; 7 mg/L

Primary: Ventilator Free Survival — 58; 19; 44 Participants

Primary: Safety Measures — 0 participants

Primary: Number of Proteins Expressed Differently in Response to Receiving Radiation Therapy — 31 Proteins

Primary: Proportion of Patients Alive and Free of Respiratory Failure Through the 30-day Trial. — 100 Percentage of of patients alive and free

Primary: Immune Reconstitution of Lymphocytopenic Sepsis Patients — 8; 7; 8 Participants

Primary: Number of Participants With Adverse Events — 20 participants

Primary: Respiratory Failure-free Survival in Participants With Moderate-severe COVID-19 Who Are Treated With ATI-450 — 50; 60 percentage of total patients

Primary: Number of Participants With Major Adverse Cardiovascular Events (MACE) — 0; 0; 2; 1 Participants

Primary: Percentage of Participants With WHO Clinical Progression Scale > 5 at Day 4 -- Severe COVID Population (WHO Clinical Progression Scale =5 at Baseline) — 26; 26…

Primary: Number of Participants With Intubation or Death — 5; 1 Participants

Primary: Change in Cognition — 0.7 Change in BACS Composite Score

Primary: Number of Participants With Graft Failure (Pilot Study Only) — 0 Participants

Primary: Full Donor Chimerism (FDC) — 6 Participants

Primary: Number of Participants With Response — 2; 2; 4; 6 participants